Biomedical subjects

Walter R Bosch

Publications and source records attributed to Walter R Bosch.

5 recordsLinked to original sources

PubMed2006

Explicit-VR transfer syntax limits the value multiplicity of DICOM data elements with decimal string (DS) value representation.

The Advanced Technology QA Consortium (ATC) has identified a problem in the encoding of DICOM RT Dose objects when these objects are converted from Implicit-VR (Little-Endian) transfer syntax to an Explicit-VR transfer syntax. There exist data elements, which can be represented in Implicit-VR Little-Endian transfer syntax but that cannot be represented in Explicit-VR Little-Endian transfer syntax.

Clinical Trials as Topic↗

PubMed2004

Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes.

PURPOSE: Computed tomography (CT)/positron emission tomography (PET)-guided intensity-modulated radiotherapy of the paraaortic lymph nodes (PALNs) has been proposed for patients with cervical carcinoma and paraaortic metastasis. This investigation attempted to determine the guidelines regarding the selection of appropriate treatment parameters (e.g., number of beams, beam geometry) and organ-specific parameters (e.g., importance weighting and tolerance dose) for intensity-modulated radiotherapy planning for the PALNs. METHODS AND MATERIALS: Patients underwent imaging using CT and PET. The images were registered, and the structures were contoured. A goal dose of 50.4 Gy and 59.4 Gy was assigned to the clinical target volume (lymph node bed) and gross tumor volume (PET-delineated PALNs), respectively. For each patient, multiple treatment plans using various beam geometries and planning parameters were executed and evaluated in terms of the dose-volume histograms of the target and critical structures. RESULTS: Acceptable sparing of the stomach, liver, and colon was achieved, regardless of the number of beams used. Sparing of the spinal cord was strongly dependent on the number and arrangement of the beams. Varying the number and arrangement of the beams affected small intestine sparing, but the amount of sparing was limited because the small intestine overlapped the target volumes, and, therefore, received the prescription dose. Adjusting the number of beams, beam angles, and prescription parameters provided minimal improvement in kidney sparing. CONCLUSION: We successfully developed treatment plans that deliver 59.4 Gy to the positive PALNs and 50.4 Gy to the paraaortic region using CT/PET-guided intensity-modulated radiotherapy.

Female↗

PubMed2003

PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study.

PURPOSE: To evaluate a treatment planning method for dose escalation to the para-aortic lymph nodes (PALNs) based on positron emission tomography (PET) with intensity-modulated radiotherapy (IMRT) for cervical cancer patients with PALN involvement. One goal of this process was not to modify the traditional treatment of the pelvic region. METHODS AND MATERIALS: PET images for 4 cervical cancer patents with PALN involvement were registered with their corresponding CT scans. Positive PALNs were identified on PET images, and the surrounding critical structures were delineated on CT images. The treatment machine central axis (CAX) was placed at the level of the L4-L5 vertebral body interspace. There were two distinct treatment regions: the para-aortic bed superior to the CAX and the whole pelvis region inferior to the CAX. IMRT was used for treatment planning of PALN bed irradiation. The positive PALNs identified on PET images were defined as the gross target volume, and the para-aortic bed was defined as the clinical target volume. The radiation doses were escalated from the conventional 45 Gy to 59.4 Gy for the gross target volume and 50.4 Gy for the clinical target volume in 33 fractions. The pelvis area was treated with conventional treatment methods, AP-PA beams to 50.4 Gy in 28 fractions with a brachytherapy implant boost. The placement of the CAX allowed the two treatment regions to be abutted using the treatment machine's independent jaws. RESULTS: Dose escalation to positive PALNs, as identified on PET images, and the PALN bed is feasible with IMRT. Treatment plans for 4 patients revealed that escalated prescription doses could be delivered to target volumes while maintaining acceptable doses to the surrounding critical structures. Strategic placement of the treatment isocenter allows the IMRT region (PALN bed) and whole pelvis fields to be treated with a relatively uniform dose distribution in the abutment region. CONCLUSION: This study indicates that PET-guided IMRT could be used in a clinical trial in an attempt to escalate doses delivered to patients with cervical cancer who have positive PALNs.

Female↗

PubMed2002

Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer.

PURPOSE: To compare conventional two-dimensional (2D) orthogonal radiography-based brachytherapy treatment planning for cervical cancer with a three-dimensional (3D) treatment planning technique based on 18F-fluoro-deoxyglucose-positron emission tomography (FDG-PET). METHODS AND MATERIALS: Eleven cervical cancer patients were included in this prospective study that evaluated one tandem and ovoid brachytherapy procedure for each patient. The patient underwent FDG-PET of the pelvis to visualize the tumor followed by a second FDG-PET scan with the FDG isotope placed inside the tandem and ovoid applicators to visualize the treatment source positions for 3D treatment planning. The tumor volumes were delineated using a binary threshold technique in which the threshold FDG-PET image intensity was 40% of the peak tumor intensity. RESULTS: FDG-PET provides a reliable estimate of the cervical cancer volume and 3D spatial relationship of the tumor to the tandem and ovoid applicators. The maximal bladder and rectal doses determined from the 3D FDG-PET dose-volume histograms were found to be higher than those obtained using 2D treatment planning. The minimal dose to the tumor volume defined by FDG-PET ranged from 50 to 475 cGy for treatment plans designed to deliver 650 cGy to Point A and exhibited an inverse correlation with tumor volume. CONCLUSION: Physiologic FDG-PET brachytherapy treatment planning is feasible and accurate relative to conventional 2D treatment planning. The use of FDG-PET offers a unique method for tumor visualization and identifies the limitations of conventional brachytherapy treatment planning for coverage of large tumors and estimation of the dose to normal structures. This technique has the potential for improving isodose tumor coverage for patients with cervical cancer while sparing critical structures.

Brachytherapy↗

PubMed2002

PET-guided three-dimensional treatment planning of intracavitary gynecologic implants.

PURPOSE: Positron emission tomography (PET) provides physiologic information that is not available from computed tomography (CT) or magnetic resonance studies. PET images may allow more accurate delineation of three-dimensional treatment planning target volumes of brachytherapy gynecologic (GYN) implants. This study evaluates the feasibility of using PET as the sole source of target, normal structure, and applicator delineation for intracavitary GYN implant treatment planning. MATERIALS AND METHODS: Standard Fletcher-Suit brachytherapy tandem and colpostat applicators were used for radiation delivery. After insertion of the applicator in the operating room, the patient was taken to a PET scanner, where 555 MBq (15 mCi) 18F-fluorodeoxyglucose (18F-FDG) was administered intravenously. Forty-five minutes later, three localization tubes containing 18F-FDG were inserted into the source afterloading compartments of the tandem and colpostat. A whole-pelvis scan was performed, and the images were transferred to a commercial brachytherapy three-dimensional treatment planning system. A Foley catheter was inserted into the urinary bladder while the patient was in the operating room. The regions of radioactivity in the three applicator tube image were contoured for reconstruction of the applicator, along with the bladder, rectum, and 18F-FDG-defined target volumes. A treatment plan was generated that included dose-volume histograms and three-dimensional dose distribution displays, allowing the physician an opportunity to determine if adequate target coverage and normal-tissue sparing had been obtained. For a more conservative approach, three-dimensional dose distributions and dose-volume histograms delivered with conventional source arrangements and loading could be observed. The accuracy of applicator localization from the PET images was verified using a water phantom containing two aluminum CT-compatible tandems. The PET-defined and CT scan applicator reconstructions were compared. RESULTS: Feasibility of using PET images for treatment planning of brachytherapy intracavitary GYN implants has been demonstrated. A phantom study demonstrated applicator reconstruction accuracy in the axial direction to be better than 2 mm. Reconstruction accuracy in the longitudinal direction (principally craniocaudal) was similar to the PET scanner's voxel size of 4.3 mm. CONCLUSIONS: Brachytherapy intracavitary GYN implant design has traditionally been based on patient tumor staging, palpation, and clinical experience. PET images have the potential to provide better spatial information about the relationship of tumor and normal structures to the applicator. This information can be used to optimize the delivery of radiation therapy treatments. Thus far, six patients have been scanned using this process.

Brachytherapy↗